0001213900-26-057766
SEC filingFY2025 delivered sharply deteriorating results with revenue down 77.9% to $1.3M and gross loss of -$363.7K, as lower sales volumes outpaced stable fixed costs while R&D costs rose for new full systems development.
Maris-Tech Ltd. reported significantly weakened FY2025 financials, reflecting a challenging transition in its defense-tech product strategy. Revenue fell 77.9% to $1.3 million from $6.1 million in FY2024, primarily due to lower sales volumes, while fixed costs remained relatively stable. This volume drop triggered a gross loss of -$363.7 thousand, inverting the prior year's $3.5 million profit and yielding a -27.1% gross margin. The swing underscores a cost structure vulnerable to revenue contraction, as stable fixed elements persisted despite reduced activity.
Operating results deteriorated further, with the loss expanding to -$5.2 million (-287.4% YoY change from -$1.3 million). This widening stemmed from increased costs related to the development of new full systems, amplifying expense pressure amid the revenue shortfall to produce an operating margin of -389.5%. Net income followed suit, reaching -$5.4 million (-338.4% YoY from -$1.2 million), with diluted EPS at -$0.67 compared to -$0.16. Financial expenses contributed, encompassing bank fees, interest, exchange differences, and remeasurement of convertible notes and investments.
Cash flow dynamics highlighted ongoing funding needs. Net cash used in operating activities rose to -$3.4 million from -$2.2 million, generating free cash flow of -$3.4 million after $23 thousand in capital expenditures (down from $191 thousand). Historically, the company has funded operations through bank loans, lines of credit, equity issuances including ordinary and preferred shares with warrants, and shareholder loans. This reliance persists amid losses.
Operationally, backlog represents accumulated pending orders with later fulfillment dates that are valid and unrecorded as revenue, consisting of executed purchase orders from new customers, long-standing relationships, and governmental agencies. Management has excluded certain orders not meeting inclusion criteria, emphasizing execution discipline.
Looking ahead, management anticipates such losses will continue until new products reach commercial profitability. Without successful commercialization or additional financing via debt or equity, planned research and development may face delays. Investors should monitor backlog conversion and new systems ramp-up for potential recovery signals, given the strategic pivot's impact on near-term performance.